Acumen Pharmaceuticals, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$123.8M | -$114.0M | -$61.1M | -$45.2M | -$19.6M |
| Operating expenses | $123.8M | $114.0M | $61.1M | $45.2M | $19.6M |
| Cash from operations | -$115.5M | -$86.2M | -$43.1M | -$35.2M | -$18.0M |
| Capital expenditure | $88,000 | $16,000 | $21,000 | $161,000 | $40,000 |
| Free cash flow | -$115.6M | -$86.2M | -$43.1M | -$35.3M | -$18.0M |
| Total assets | $122.8M | $239.0M | $310.1M | $196.6M | $230.3M |
| Total liabilities | $52.4M | $57.2M | $43.2M | $7.8M | $5.1M |
| Total debt | $31.2M | $29.4M | — | — | — |
Shares outstanding 72.2M · Free float 88.6%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.